NCT04953104View on ClinicalTrials.gov

ARID1A and/or KDM6A Mutation and CXCL13 Expression

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 21, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial CarcinomaLocally Advanced Urethral Urothelial CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis Urothelial CarcinomaMetastatic Ureter Urothelial CarcinomaMetastatic Urethral Urothelial CarcinomaMetastatic Urothelial CarcinomaRecurrent Bladder Urothelial CarcinomaRecurrent Renal Pelvis Urothelial CarcinomaRecurrent Ureter Urothelial CarcinomaRecurrent Urethral Urothelial CarcinomaRecurrent Urothelial CarcinomaStage III Bladder Cancer AJCC v8Stage III Renal Pelvis Cancer AJCC v8Stage III Ureter Cancer AJCC v8Stage III Urethral Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8Stage IIIB Bladder Cancer AJCC v8Stage IV Bladder Cancer AJCC v8Stage IV Renal Pelvis Cancer AJCC v8Stage IV Ureter Cancer AJCC v8Stage IV Urethral Cancer AJCC v8Stage IVA Bladder Cancer AJCC v8Stage IVB Bladder Cancer AJCC v8Unresectable Bladder Urothelial CarcinomaUnresectable Renal Pelvis Urothelial CarcinomaUnresectable Ureter Urothelial CarcinomaUnresectable Urethral Urothelial CarcinomaUnresectable Urothelial Carcinoma
Interventions
OTHER

Diagnostic Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

DRUG

Relatlimab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER